The 'Uncompany' Answer to Building a Company

Life scientists who want to see their ideas pay off but who don't want to get bogged down in bureaucratic drudgery can take heart from a new trend in business organization. Instead of pushing scientists to hire and oversee pricey financial and legal and regulatory experts, a new breed of barebones biopharmaceutical venture capitalists invest early, when the inventors first create their companies, and recruit outside administrators to handle the management. Charles Hadley and Hal Broderson hold

Written byPeg Brickley
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

Charles Hadley and Hal Broderson hold executive positions in each of the eight new companies their firm, Rock Hill Ventures in West Conshohocken, Pa., has helped start up; they build the management structure while the scientists work out the product design. "Part of the advantage is you don't have a lot of infrastructure baggage," Broderson says. "When problems happen, you can turn the burn rate on and off like a spigot." The "burn rate," or the amount of cash a company spends during the development stage, is something venture capitalists watch closely. The more business Hadley and Broderson take on, the less money the start-ups have to spend and the further Rock Hill's invested capital stretches. If a buyer offers a nice price for the business early on, no executive egos will get in the way of a deal.

Other venture firms are catching on to the idea, including two ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies